Seer, Inc. (NASDAQ:SEER) Shares Purchased by Barclays PLC

Barclays PLC lifted its stake in Seer, Inc. (NASDAQ:SEER) by 34.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,426 shares of the company’s stock after purchasing an additional 16,382 shares during the period. Barclays PLC owned approximately 0.10% of Seer worth $127,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Seer in the second quarter valued at about $30,000. Point72 DIFC Ltd acquired a new stake in shares of Seer in the second quarter valued at about $35,000. Quadrature Capital Ltd lifted its stake in shares of Seer by 301.7% in the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after purchasing an additional 42,875 shares during the period. American Century Companies Inc. lifted its stake in shares of Seer by 42.1% in the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock valued at $104,000 after purchasing an additional 18,302 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Seer in the third quarter valued at about $123,000. Institutional investors and hedge funds own 75.20% of the company’s stock.

Seer Trading Down 1.6 %

NASDAQ:SEER opened at $2.41 on Thursday. The firm has a 50-day moving average price of $2.34 and a two-hundred day moving average price of $1.98. Seer, Inc. has a twelve month low of $1.51 and a twelve month high of $2.63. The company has a market capitalization of $142.11 million, a P/E ratio of -1.85 and a beta of 1.57.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.